JP2005518361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518361A5 JP2005518361A5 JP2003546874A JP2003546874A JP2005518361A5 JP 2005518361 A5 JP2005518361 A5 JP 2005518361A5 JP 2003546874 A JP2003546874 A JP 2003546874A JP 2003546874 A JP2003546874 A JP 2003546874A JP 2005518361 A5 JP2005518361 A5 JP 2005518361A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- concentration
- alleviating
- riboflavin
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 6
- 239000004473 Threonine Substances 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- 235000004279 alanine Nutrition 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 229960003121 arginine Drugs 0.000 claims 6
- 229960003104 ornithine Drugs 0.000 claims 6
- 229960002477 riboflavin Drugs 0.000 claims 6
- 235000019192 riboflavin Nutrition 0.000 claims 6
- 239000002151 riboflavin Substances 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 235000016709 nutrition Nutrition 0.000 claims 4
- 208000030212 nutrition disease Diseases 0.000 claims 4
- 229960003080 taurine Drugs 0.000 claims 4
- 231100000331 toxic Toxicity 0.000 claims 4
- 230000002588 toxic effect Effects 0.000 claims 4
- 230000004143 urea cycle Effects 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
- 229960002173 citrulline Drugs 0.000 claims 2
- 235000013477 citrulline Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- OQGRFQCUGLKSAV-UHFFFAOYSA-N n-(2,6-dioxopiperidin-3-yl)-2-phenylacetamide Chemical compound C1CC(=O)NC(=O)C1NC(=O)CC1=CC=CC=C1 OQGRFQCUGLKSAV-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 235000009697 arginine Nutrition 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/995,010 US20030105104A1 (en) | 2001-11-27 | 2001-11-27 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| PCT/US2002/037354 WO2003045372A1 (en) | 2001-11-27 | 2002-11-21 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005518361A JP2005518361A (ja) | 2005-06-23 |
| JP2005518361A5 true JP2005518361A5 (https=) | 2006-01-05 |
| JP4614660B2 JP4614660B2 (ja) | 2011-01-19 |
Family
ID=25541300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546874A Expired - Fee Related JP4614660B2 (ja) | 2001-11-27 | 2002-11-21 | 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20030105104A1 (https=) |
| EP (1) | EP1450781B1 (https=) |
| JP (1) | JP4614660B2 (https=) |
| KR (1) | KR100953483B1 (https=) |
| CN (1) | CN100358527C (https=) |
| AT (1) | ATE330595T1 (https=) |
| BR (1) | BR0214430A (https=) |
| CA (1) | CA2468133C (https=) |
| DE (1) | DE60212693T2 (https=) |
| EA (1) | EA009516B1 (https=) |
| HU (1) | HU230986B1 (https=) |
| IL (2) | IL162141A0 (https=) |
| MX (1) | MXPA04004994A (https=) |
| NO (1) | NO332858B1 (https=) |
| NZ (1) | NZ532833A (https=) |
| PL (1) | PL353656A1 (https=) |
| RO (1) | RO121173B1 (https=) |
| SI (1) | SI21542A (https=) |
| UA (1) | UA78977C2 (https=) |
| WO (1) | WO2003045372A1 (https=) |
| ZA (1) | ZA200404115B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060293335A1 (en) * | 2002-08-02 | 2006-12-28 | Qishou Xu | Riboflavin derivative and its manufacture and uses |
| US20070248693A1 (en) * | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
| US20060035981A1 (en) * | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| RU2240788C1 (ru) * | 2003-09-09 | 2004-11-27 | Воронежская государственная медицинская академия им. Н.Н. Бурденко | Детоксикационное средство |
| SG158073A1 (en) | 2004-11-26 | 2010-01-29 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| WO2008008084A2 (en) * | 2005-09-19 | 2008-01-17 | Cdm Optics, Inc. | Task-based imaging systems |
| MY163134A (en) * | 2006-03-15 | 2017-08-15 | Suntory Holdings Ltd | Composition containing riboflavin and sesamin-class compounds |
| US20080249001A1 (en) * | 2006-10-25 | 2008-10-09 | Ajinomoto Co. Inc. | Agents that alleviate side-effects caused by chemotherapy agents |
| WO2008105384A1 (ja) * | 2007-02-26 | 2008-09-04 | Kyowa Hakko Bio Co., Ltd. | シトルリン含有錠剤 |
| JP5591533B2 (ja) | 2007-03-15 | 2014-09-17 | サントリーホールディングス株式会社 | 抗疲労剤 |
| US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| EP3011843A1 (en) | 2008-09-19 | 2016-04-27 | Nestec S.A. | Nutritional support of the immune system during anti-cancer treatment |
| AU2014200578B2 (en) * | 2008-09-19 | 2016-08-11 | Société des Produits Nestlé S.A. | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| CA2757373C (en) | 2009-04-03 | 2018-05-08 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| EA201691430A1 (ru) | 2009-06-08 | 2017-02-28 | ЮСиЭл БИЗНЕС ПиЭлСи | Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата |
| US8449512B2 (en) | 2010-04-09 | 2013-05-28 | Davinci Biomedical Research Products Inc. | Stoma stabilitating device and method |
| EP2397458A1 (en) * | 2010-06-21 | 2011-12-21 | Lunamed AG | Organic salts and co-crystals of phenylbutyric acid |
| CN104997803B (zh) * | 2010-07-22 | 2019-07-09 | 雷文制药有限公司 | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物 |
| KR101758424B1 (ko) | 2010-09-24 | 2017-07-14 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| MX360062B (es) | 2010-10-06 | 2018-10-22 | Ocera Therapeutics Inc | Metodos de elaboracion de fenilacetato de l-ornitina. |
| RU2623878C2 (ru) | 2010-12-10 | 2017-06-29 | Броади Хэлс Сайенсис, Эл Эл Си | Применение жасмоната для лечения нарушения функции мочевого пузыря |
| JP6090836B2 (ja) * | 2011-02-17 | 2017-03-08 | Ｅａファーマ株式会社 | 化学療法剤の抗腫瘍活性増強剤 |
| AU2012278813B2 (en) * | 2011-07-07 | 2016-09-08 | Research Cancer Institute Of America | Systems, methods, and formulations for treating cancer |
| KR101969199B1 (ko) | 2013-03-11 | 2019-04-15 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법 |
| JP6742904B2 (ja) * | 2013-11-08 | 2020-08-19 | レガシー ヘルスケア リミテッド | ガンおよびガン共存症の治療に使用するための組成物 |
| JP6598425B2 (ja) * | 2014-02-27 | 2019-10-30 | 花王株式会社 | 疲労の評価方法 |
| US10039735B2 (en) | 2014-11-24 | 2018-08-07 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| EP3337473A4 (en) | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| CN105495582A (zh) * | 2015-12-11 | 2016-04-20 | 北京康比特体育科技股份有限公司 | 一款抗疲劳、促恢复的保健食品氨基酸组合物 |
| WO2018208677A1 (en) | 2017-05-11 | 2018-11-15 | Ocera Therapeutics, Inc. | Processes of making l-ornithine phenylacetate |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
| JPS58126767A (ja) * | 1982-01-22 | 1983-07-28 | Ajinomoto Co Inc | 肝臓病患者用栄養組成物 |
| ATE54826T1 (de) * | 1985-10-23 | 1990-08-15 | Mulli Kurt Nachf Gmbh | Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung. |
| US5045468A (en) * | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
| DK0421309T4 (da) * | 1989-10-02 | 2003-04-22 | Associated British Foods Plc | Proteinhydrolysater |
| US5292773A (en) * | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
| WO1994014458A1 (en) * | 1992-12-23 | 1994-07-07 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
| US5571783A (en) * | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| FR2705765B1 (fr) * | 1993-04-29 | 1995-08-18 | Eurofours Sa | Porte de four. |
| NZ248605A (en) * | 1993-05-28 | 1994-12-22 | Abbott Lab | Enteral nutritional product comprising protein and fat |
| US5547927A (en) * | 1993-05-28 | 1996-08-20 | Abbott Laboratories | Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| US5776913A (en) * | 1995-10-10 | 1998-07-07 | Colgate Palmolive Company | Therapeutic diet for metabolic abnormalities found in animals with lymphoma |
| ATE310505T1 (de) * | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
| US5817927A (en) * | 1997-04-11 | 1998-10-06 | Betzdearborn Inc. | Method and apparatus for monitoring water process equipment |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| EP1062879B1 (en) | 1999-06-26 | 2003-08-27 | B. Braun Melsungen Ag | Aqueous solution for the parenteral nutrition |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| US6377094B1 (en) * | 2002-03-25 | 2002-04-23 | Oak Technology, Inc. | Arbitrary waveform synthesizer using a free-running ring oscillator |
-
2001
- 2001-11-27 US US09/995,010 patent/US20030105104A1/en not_active Abandoned
-
2002
- 2002-04-26 PL PL02353656A patent/PL353656A1/xx not_active Application Discontinuation
- 2002-11-21 CN CNB028236068A patent/CN100358527C/zh not_active Expired - Fee Related
- 2002-11-21 DE DE60212693T patent/DE60212693T2/de not_active Expired - Lifetime
- 2002-11-21 HU HU0402240A patent/HU230986B1/hu not_active IP Right Cessation
- 2002-11-21 AT AT02789801T patent/ATE330595T1/de not_active IP Right Cessation
- 2002-11-21 JP JP2003546874A patent/JP4614660B2/ja not_active Expired - Fee Related
- 2002-11-21 IL IL16214102A patent/IL162141A0/xx unknown
- 2002-11-21 EP EP02789801A patent/EP1450781B1/en not_active Expired - Lifetime
- 2002-11-21 EA EA200400737A patent/EA009516B1/ru not_active IP Right Cessation
- 2002-11-21 BR BR0214430-1A patent/BR0214430A/pt not_active Application Discontinuation
- 2002-11-21 WO PCT/US2002/037354 patent/WO2003045372A1/en not_active Ceased
- 2002-11-21 CA CA2468133A patent/CA2468133C/en not_active Expired - Fee Related
- 2002-11-21 UA UA20040605059A patent/UA78977C2/uk unknown
- 2002-11-21 NZ NZ532833A patent/NZ532833A/en not_active IP Right Cessation
- 2002-11-21 RO ROA200400481A patent/RO121173B1/ro unknown
- 2002-11-21 SI SI200220037A patent/SI21542A/sl not_active IP Right Cessation
- 2002-11-21 MX MXPA04004994A patent/MXPA04004994A/es active IP Right Grant
- 2002-11-21 KR KR1020047007754A patent/KR100953483B1/ko not_active Expired - Fee Related
-
2004
- 2004-05-24 IL IL162141A patent/IL162141A/en not_active IP Right Cessation
- 2004-05-26 ZA ZA2004/04115A patent/ZA200404115B/en unknown
- 2004-06-07 NO NO20042364A patent/NO332858B1/no not_active IP Right Cessation
-
2005
- 2005-04-18 US US11/108,277 patent/US7427619B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005518361A5 (https=) | ||
| CA2468133A1 (en) | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | |
| ES2221385T3 (es) | Preparaciones de gabapentina y pregabalina estabilizadas con aminoacidos y procedimiento para prepararlas. | |
| JP2022159555A (ja) | 神経疾患を治療するための方法 | |
| JP2018012722A5 (https=) | ||
| WO2010051541A3 (en) | Compositions containing delta-9-thc-amino acid esters and process of preparation | |
| MXPA06002344A (es) | Composiciones farmaceuticas y metodo para usar levodopa y carbidopa. | |
| WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
| NZ592510A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| EP0182356B1 (en) | Nutrient compositions | |
| RU2014121518A (ru) | Растворы на основе мелатонина и порошки для их получения | |
| WO2002074302A1 (en) | Amino acid compositions for ameliorating liver failure | |
| US20060166931A1 (en) | Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| JP2006508972A5 (https=) | ||
| CN1703214A (zh) | 改善中枢神经功能的氨基酸组合物 | |
| ME02149B (me) | FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE | |
| EA200501129A1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| JP2003504395A5 (https=) | ||
| KR950010884A (ko) | 사람 및 동물에서 염증성 반응을 일으키는 공격 또는 패혈증 치료용의 아미노산계 조성물 | |
| JP2006506440A5 (https=) | ||
| ES2360759T3 (es) | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. | |
| WO2017024953A1 (zh) | 尼莫地平水溶性衍生物及其制备方法和应用 | |
| YU81101A (sh) | Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija | |
| JP2008532601A5 (https=) | ||
| WO2002074303A1 (en) | Amino acid compositions for ameliorating kidney failure |